BonnieS.GlissonMD

Oncology • Houston, TX

Professor of Medicine, University Tex Houston

Join to view full profile

Dr. Glisson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Glisson's full profile

Already have an account?

Office
1515 Holcombe Blvd
Houston, TX 77030
Phone+1 713-792-6363

Fax+1 713-792-1220

Education & Training

University of FloridaFellowship, Hematology and Medical Oncology, 1982 - 1985
University of Virginia Medical CenterResidency, Internal Medicine, 1979 - 1982
Ohio State University College of MedicineClass of 1979

Certifications & Licensure

TX State Medical License 1986 - 2025
OK State Medical License 2020 - 2021
FL State Medical License 1983 - 1987
OH State Medical License 1985 - 1986
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly, 2002-2014
Top Doctors:SE Texas Castle Connolly, 2013
America's Top Doctors for Cancer Castle Connolly, 2005-2013
Super Doctor SuperDoctors.com
Join now to see all

Clinical Trials

Fenretinide in Treating Patients With Recurrent or Metastatic Head and Neck Cancer Start of enrollment: 2000 Sep 01
Completed
Phase 2
ZD1839 (Iressa) for Recurrent or Metastatic Squamous Cell Carcinoma of the Skin Start of enrollment: 2004 May 01
Completed
Phase 2
Erlotinib and Docetaxel With Concomitant Boost Radiation Therapy (XRT) for Head and Neck Squamous Cell Carcinoma (HNSCC) Start of enrollment: 2005 Apr 01
Completed
Phase 1
Gefitinib in Treating Patients Who Are Undergoing Surgery and/or Radiation Therapy for Locally Advanced or Recurrent Squamous Cell Skin Cancer Start of enrollment: 2005 Mar 01
Completed
Phase 2
Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer Start of enrollment: 2005 Jul 01
Completed
Phase 2
Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC) Start of enrollment: 2006 Nov 01
Withdrawn
Phase 1, Phase 2
Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes Start of enrollment: 2009 Nov 01
Completed
Phase 2
Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin Start of enrollment: 2011 Feb 01
Terminated
Phase 2
Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma Start of enrollment: 2011 Mar 10
Completed
Phase 2
Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer Start of enrollment: 2013 Jul 01
Completed
Phase 1, Phase 2
A Prospective Observational Study to Evaluate Acute Kidney Injury Biomarkers In Patients Receiving First Cycle of Cisplatin Chemotherapy for Head and Neck Cancers Start of enrollment: 2012 Sep 01
Unknown status
Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer Start of enrollment: 2016 Jan 25
Completed
Phase 2
Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer Start of enrollment: 2018 Apr 04
Terminated
Phase 2
A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC Start of enrollment: 2018 Nov 30
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

496 citations
Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer
Triparna Sen, B. Leticia Rodriguez, Limo Chen, Carminia Maria Della Corte, Naoto Morikawa
Cancer Discovery. 2019-05-01
1243 citations
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Mark G. Kris, Bruce E. Johnson, Lynne D. Berry, David J. Kwiatkowski, A. John Iafrate
JAMA. 2014-05-21
14 citations
Evaluation of programmed death ligand 1 expression in cytology to determine eligibility for immune checkpoint inhibitor therapy in patients with head and neck squamous...
Zhonghua Liu, Michelle A. Williams, John Stewart, Bonnie S. Glisson, Clifton D. Fuller
Cancer Cytopathology. 2021-08-10

Journal Articles

PI3‐Kinase Pathway Biomarkers in Oral Cancer and Tumor Immune Cells
Bonnie S Glisson, Jeffrey Myers, N Jr William, Renata Ferrarotto, Head & Neck
Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients with Incurable Human Papillomavirus 16–Related Cancer
Erminia Massarelli, William William, Ming Guo, Merrill Kies, Bonnie Glisson, Hai Tran, Faye Johnson, Renata Ferrarotto, Lei Feng, JAMA
Landscape of EGFR -Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Post-Progression in EGFR-Mutant NSCLC
Stephen G Swisher, Vassiliki A Papadimitrakopoulou, John V Heymach, Jack A Roth, Jianjun Zhang, William N William, Bonnie S Glisson, Clinical Cancer Research

Press Mentions

MD Anderson Research Highlights for March 9, 2022March 9th, 2022
How I Dealt with My Worst Lung Cancer Symptom and Side EffectDecember 13th, 2018
An Immunotherapy Clinical Trial Stabilized My DiseaseNovember 29th, 2018
Join now to see all

Grant Support

Career Development ProgramNational Cancer Institute2008–2011
In Vitro Correlates Of Drug Sensitivity In Lung CancerNational Cancer Institute1992–1993
NCI Clinical Investigator Award ProgramNational Cancer Institute1987–1989